G 4460

Drug Profile

G 4460

Alternative Names: c-myb antisense oligonucleotide G4460; G4460; INX 3001; INXC 3001; LR3001

Latest Information Update: 09 Mar 2015

Price : $50

At a glance

  • Originator Temple University
  • Developer Genta (CEASED); University of Pennsylvania
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Proto oncogene proteins c myb inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic myeloid leukaemia; Leukaemia

Most Recent Events

  • 20 May 2008 Discontinued - Phase-I for Leukaemia in USA (IV)
  • 20 May 2008 Discontinued - Preclinical for Chronic myeloid leukaemia in USA (Parenteral)
  • 26 Oct 2006 Phase-I clinical trials in Leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top